vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and PCB BANCORP (PCB). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $29.2M, roughly 1.3× PCB BANCORP). On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 11.3%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
IBRX vs PCB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $29.2M |
| Net Profit | $-61.9M | — |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 45.0% |
| Net Margin | -161.8% | — |
| Revenue YoY | 407.0% | 11.3% |
| Net Profit YoY | -4.7% | — |
| EPS (diluted) | $-0.06 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $29.2M | ||
| Q3 25 | $32.1M | $30.4M | ||
| Q2 25 | $26.4M | $29.3M | ||
| Q1 25 | $16.5M | $26.9M | ||
| Q4 24 | $7.6M | $26.2M | ||
| Q3 24 | $6.1M | $25.3M | ||
| Q2 24 | — | $24.2M | ||
| Q1 24 | — | $23.9M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-67.3M | $11.4M | ||
| Q2 25 | $-92.6M | $9.1M | ||
| Q1 25 | $-129.6M | $7.7M | ||
| Q4 24 | $-59.2M | — | ||
| Q3 24 | $-85.7M | $7.8M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $4.7M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 45.0% | ||
| Q3 25 | -173.5% | 52.3% | ||
| Q2 25 | -269.8% | 43.3% | ||
| Q1 25 | -390.1% | 40.2% | ||
| Q4 24 | -919.0% | 39.3% | ||
| Q3 24 | -1314.3% | 42.2% | ||
| Q2 24 | — | 36.3% | ||
| Q1 24 | — | 27.2% |
| Q4 25 | -161.8% | — | ||
| Q3 25 | -209.8% | 37.5% | ||
| Q2 25 | -350.3% | 31.0% | ||
| Q1 25 | -784.9% | 28.8% | ||
| Q4 24 | -783.4% | — | ||
| Q3 24 | -1404.0% | 30.8% | ||
| Q2 24 | — | 25.9% | ||
| Q1 24 | — | 19.6% |
| Q4 25 | $-0.06 | $0.65 | ||
| Q3 25 | $-0.07 | $0.78 | ||
| Q2 25 | $-0.10 | $0.62 | ||
| Q1 25 | $-0.15 | $0.53 | ||
| Q4 24 | $-0.08 | $0.46 | ||
| Q3 24 | $-0.14 | $0.52 | ||
| Q2 24 | — | $0.43 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $207.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $390.0M |
| Total Assets | $501.9M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $207.1M | ||
| Q3 25 | $257.8M | $369.5M | ||
| Q2 25 | $153.7M | $263.6M | ||
| Q1 25 | $61.6M | $214.3M | ||
| Q4 24 | $149.8M | $198.8M | ||
| Q3 24 | $130.4M | $193.1M | ||
| Q2 24 | — | $177.6M | ||
| Q1 24 | — | $239.8M |
| Q4 25 | $-500.5M | $390.0M | ||
| Q3 25 | $-524.3M | $384.5M | ||
| Q2 25 | $-570.7M | $376.5M | ||
| Q1 25 | $-591.4M | $370.9M | ||
| Q4 24 | $-489.1M | $363.8M | ||
| Q3 24 | $-745.1M | $362.3M | ||
| Q2 24 | — | $353.5M | ||
| Q1 24 | — | $350.0M |
| Q4 25 | $501.9M | $3.3B | ||
| Q3 25 | $519.0M | $3.4B | ||
| Q2 25 | $402.1M | $3.3B | ||
| Q1 25 | $303.8M | $3.2B | ||
| Q4 24 | $382.9M | $3.1B | ||
| Q3 24 | $364.6M | $2.9B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $26.6M |
| Free Cash FlowOCF − Capex | $-71.3M | $24.4M |
| FCF MarginFCF / Revenue | -186.2% | 83.6% |
| Capex IntensityCapex / Revenue | 2.4% | 7.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $46.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $26.6M | ||
| Q3 25 | $-68.9M | $16.4M | ||
| Q2 25 | $-79.7M | $4.9M | ||
| Q1 25 | $-85.9M | $2.3M | ||
| Q4 24 | $-85.1M | $39.0M | ||
| Q3 24 | $-98.8M | $11.9M | ||
| Q2 24 | — | $14.6M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | $-71.3M | $24.4M | ||
| Q3 25 | $-69.6M | $16.2M | ||
| Q2 25 | $-80.8M | $3.8M | ||
| Q1 25 | $-87.0M | $1.6M | ||
| Q4 24 | $-87.3M | $34.9M | ||
| Q3 24 | $-101.6M | $11.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | — | $6.0M |
| Q4 25 | -186.2% | 83.6% | ||
| Q3 25 | -217.2% | 53.2% | ||
| Q2 25 | -305.9% | 13.1% | ||
| Q1 25 | -526.9% | 6.0% | ||
| Q4 24 | -1155.4% | 133.2% | ||
| Q3 24 | -1663.2% | 46.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | — | 25.2% |
| Q4 25 | 2.4% | 7.5% | ||
| Q3 25 | 2.3% | 0.8% | ||
| Q2 25 | 4.1% | 3.7% | ||
| Q1 25 | 6.8% | 2.8% | ||
| Q4 24 | 28.0% | 15.5% | ||
| Q3 24 | 45.7% | 0.1% | ||
| Q2 24 | — | 7.3% | ||
| Q1 24 | — | 9.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | — | 1.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
